Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aclarion Inc (ACON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ACON (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.77% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.41M USD | Price to earnings Ratio - | 1Y Target Price 11758.41 |
Price to earnings Ratio - | 1Y Target Price 11758.41 | ||
Volume (30-day avg) 388470 | Beta 1.08 | 52 Weeks Range 9.75 - 3554.69 | Updated Date 04/3/2025 |
52 Weeks Range 9.75 - 3554.69 | Updated Date 04/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5658.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8995.34% |
Management Effectiveness
Return on Assets (TTM) -127.69% | Return on Equity (TTM) -745.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6010216 | Price to Sales(TTM) 129.96 |
Enterprise Value 6010216 | Price to Sales(TTM) 129.96 | ||
Enterprise Value to Revenue 121.94 | Enterprise Value to EBITDA -0.56 | Shares Outstanding 507995 | Shares Floating 31117 |
Shares Outstanding 507995 | Shares Floating 31117 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 4 | Target Price 1.3 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aclarion Inc
Company Overview
History and Background
Aclarion Inc. is a medical device company focused on developing and commercializing novel technologies for the diagnosis and treatment of spine and other orthopedic conditions. The company's focus is on using Magnetic Resonance Spectroscopy (MRS) to identify biomarkers in the spine.
Core Business Areas
- Nociscan: Aclarion's flagship product is Nociscan, a MR spectroscopy based test used to identify painful spinal disc levels to assist physicians with treatment planning.
Leadership and Structure
The leadership team consists of Brent Stutz, CEO, among other executives. The company operates with a structure typical for a medical device company, including research, development, and commercialization teams.
Top Products and Market Share
Key Offerings
- Nociscan: Nociscan is a diagnostic platform utilizing MR Spectroscopy to identify painful spinal discs, assisting surgeons in patient selection. Market share is not publicly available due to the novel nature of the test and the lack of direct comparators. Competitors include traditional diagnostic imaging methods and subjective clinical assessments.
Market Dynamics
Industry Overview
The spine surgery market is substantial and growing. Current market challenges include high failure rates of spinal fusions, indicating a need for improved diagnostic tools for identifying appropriate surgical candidates.
Positioning
Aclarion positions itself as a leader in advanced diagnostic solutions for spine care, aiming to improve surgical outcomes through enhanced patient selection.
Total Addressable Market (TAM)
The total addressable market is substantial, encompassing the broader spine surgery and diagnostics market, estimated at billions of dollars globally. Aclarion aims to capture a segment of this market by offering a more precise diagnostic tool.
Upturn SWOT Analysis
Strengths
- Novel diagnostic technology
- Potential to improve surgical outcomes
- Focus on a specific clinical need
Weaknesses
- Limited commercial traction
- Requires adoption by surgeons
- Reimbursement hurdles
Opportunities
- Expanding clinical validation
- Securing reimbursement coverage
- Strategic partnerships
Threats
- Competition from established diagnostic methods
- Lack of market acceptance
- Regulatory challenges
Competitors and Market Share
Key Competitors
- SIFY
- NXTC
- ISRG
Competitive Landscape
Aclarion's competitive advantage lies in its novel technology, but it faces challenges from established companies with broader product portfolios and market presence.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been limited as the company focuses on achieving commercial traction for Nociscan.
Future Projections: Future growth is dependent on the adoption of Nociscan by surgeons and healthcare providers.
Recent Initiatives: Recent initiatives involve clinical studies to demonstrate the effectiveness of Nociscan.
Summary
Aclarion is a medical device company with a novel technology for spinal disc diagnosis. Its success hinges on securing surgeon adoption and reimbursement. Its weakness comes from needing to prove itself against bigger competitors in the market.
Similar Companies
ISRG
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
NXTC
NextCure Inc
NXTC
NextCure Inc
SIFY
Sify Technologies Limited
SIFY
Sify Technologies Limited
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (if available)
- Industry Reports
- Press Releases
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclarion Inc
Exchange NASDAQ | Headquaters Broomfield, CO, United States | ||
IPO Launch date 2022-04-22 | CEO, President & Director Mr. Brent Ness | ||
Sector Healthcare | Industry Health Information Services | Full time employees 4 | Website https://www.aclarion.com |
Full time employees 4 | Website https://www.aclarion.com | ||
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN software application, a non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also develops NOCISCAN Post-Processor Suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.